Progenics Oioioioi - 500 Beiträge pro Seite

[Xedi]

Gibt es hier was neues ?

Progenics mit 14,6 % im Plus.

Weiß jemand mehr?

Gruß X

[Xedi]

nu schon 16,4 % und keiner weiss bescheid.

[Zocker45]

Xedi,

nimms einfach hin, 150% Chance!

Gruß Angy

[Xedi]

@ zocker 45

Wat denn heute noch ?

Gruß X

[Xedi]

Hab doch noch was gefunden.



Progenics and Cytogen Develop Antibodies to Treat Prostate Cancer
Friday, November 10, 2000 07:35:21 AM - PR Newswire


AMSTERDAM, Netherlands, Nov 10, 2000 /PRNewswire via COMTEX/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Cytogen Corporation (Nasdaq: CYTO) today announced their development of a new generation of monoclonal antibodies that have potential utility in the treatment of prostate cancer. These antibodies are directed against prostate specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. The antibodies are being developed for therapy in "naked," radiolabelled and toxin-conjugated forms capable of selectively targeting and destroying PSMA-expressing cancer cells. The preclinical findings were reported here at the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy.

The novel antibodies uniquely recognize the three-dimensional structure of PSMA as presented on cancer cells. Antibodies which bind to such "conformational" structures represent excellent candidates for therapy since they typically possess higher affinity and specificity for the target antigens than antibodies designed to recognize only segments or linear sequences, independent of the physical structure of the target. The findings were described in a presentation by Robert J. Israel, M.D., Vice President of Medical Affairs at Progenics.

"The reactivity profile of our monoclonal antibodies makes them preferred therapeutic candidates over prior generation PSMA antibodies," said Dr. Israel. "We look forward to optimizing the therapeutic utility of these antibodies using the best available preclinical models of human prostate cancer in anticipation of human clinical testing."

In addition to the antibody strategy described above, the joint venture between Progenics and Cytogen is also pursuing a parallel development program for the development of therapeutic vaccines which target PSMA. Novel viral vector and purified protein vaccines for use both individually and in prime-boost combinations are in late stage pre-clinical development. In animal studies, the vaccines have generated potent and specific immune responses to cell-surface PSMA. The two vaccine programs are directed at stimulating a patient`s immune system to eradicate his own cancer. The companies anticipate that vaccine, as well as antibody-based therapies, could be tested in patients next year.

The PSMA gene was first discovered by scientists at Memorial Sloan-Kettering Cancer Center in New York City. PSMA is a cell-surface protein abundantly expressed on prostate cancer cells and therefore is an attractive target for vaccine and antibody-based cancer immunotherapies. Further work has demonstrated that PSMA is also present at high levels on newly formed blood vessels (neovasculature) needed for the growth and survival of many types of solid tumors. These observations suggest that if PSMA-targeted therapies exhibit anti-angiogenesis effects, they may be valuable in treating a broad range of cancers.

Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development and commercialization of products for the treatment and prevention of cancer, viral and other life-threatening diseases. The Company`s lead HIV product, PRO 542, has completed two Phase I/II clinical trials, and two follow-on HIV products, PRO 367 and PRO 140, are preparing to commence Phase I/II trials. Progenics also has collaborations with F. Hoffmann-La Roche Ltd in the area of HIV fusion co-receptors, and with American Home Products and Pharmacopeia, Inc. focusing on HIV attachment and fusion. The Company`s most advanced product, GMK, is a cancer vaccine in pivotal Phase III clinical trials for the treatment of malignant melanoma. The Company is also prepared to commence Phase II trials with a second cancer vaccine, MGV, with broad application to a variety of cancers. GMK and MGV are the subject of a collaboration with Bristol-Myers Squibb Company. The Company, with Cytogen Corporation, has formed a joint venture focusing on the development of cancer immunotherapies based on PSMA (Prostate Specific Membrane Antigen) technology. The Company is also developing a novel small-molecule antioxidant, DHA, to treat stroke and other disorders.

Cytogen Corporation is a biopharmaceutical company in Princeton, New Jersey whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed to development of novel products for the diagnosis, imaging, staging and treatment of cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises three FDA-approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; OncoScint CR/OV(R), a diagnostic imaging agent for colorectal and ovarian cancerproduct. The companies do not have a policy of updating or revising forward-looking statements, and thus it should not be assumed that the companies` silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.


mfg Xedi

[Xedi]

Scheiße wieder bei 27 §.

War wohl nur ein kurzes Strohfeuer.

mfg X

[dereinzigepsycho]

Wo finde ich mehr infos zu Progenics?

[Xedi]

Unter barchart.com,
dann PGNX eingeben.

[windelwinni]

@ wer sie noch hat - und wer sie noch nicht hat.

In den USA aktuell 20% Prozent im Plus.


TARRYTOWN, N.Y., Jan. 24 /PRNewswire/ -- Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) has announced today
publication of the results of a clinical trial of its cancer vaccine, MGV.
Cancer patients from New York`s Memorial Sloan-Kettering Cancer
Center were treated with the new vaccine which was found to be free of
significant toxicity and to induce antibodies against two different
targets on cancer cells. The trial results are published in the current
issue of Clinical Cancer Research

[Donkosak]

Hallo an Alle!Seit Ihr verstorben oder eingeschlafen?Na so langweilig ist die Aktie nun wirklich nicht .Um mal das ganze wieder in Schwung zu bringen was Neues!

PROGENICS` EXPERIMENTAL DRUG, PRO 140, LOWERED VIRAL LOADS TO UNDETECTABLE LEVELS IN ANIMAL MODEL OF HIV INFECTION


Monoclonal antibody inhibited replication of HIV in vivo by blocking viral entry

Seattle, WA, April 09, 2001 -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced that its experimental drug, PRO 140, reduced viral burdens to undetectable levels in a well-recognized animal model of HIV (human immunodeficiency virus) infection. In mice treated with PRO 140, initially high HIV concentrations became undetectable for up to nine days after a single dose of the experimental drug. PRO 140 is a monoclonal antibody that belongs to a new class of drugs designed to block HIV from entering and infecting cells, a therapeutic approach not exploited by currently approved HIV therapies. The scientific results were presented today at the 14th International Conference on Antiviral Research in Seattle.

“Today’s findings represent an important first demonstration of the in vivo potency of PRO 140,” said William C. Olson, Ph.D., Vice President of Research and Development at Pro-genics. “Future studies will explore the magnitude and duration of viral suppression attainable with multiple doses of PRO 140 used alone and in combination with other agents.”

The Company believes that a large body of experimental evidence supports PRO 140 as a promising therapeutic candidate. In previous laboratory studies:


PRO 140 potently blocked each of 17 HIV isolates that are typical of those associated with person-to-person transmission of the virus and with the asymptomatic phase of in-fection.

PRO 140 was shown to be effective at protecting both primary T cells and macrophages, the immune system cells that are the major targets for HIV infection.

HIV did not develop resistance to PRO 140 despite continued exposure to the drug for 40 weeks, a period during which emergence of resistance is usually observed for other classes of anti-viral agents.
For HIV to enter and infect human cells, it must interact sequentially with two receptors (CD4 and CCR5) normally present on the outer membrane of certain immune system cells. PRO 140 is designed to bind to a portion of the CCR5 receptor and block HIV entry while having no apparent effect on the normal function of CCR5.

While HIV normally infects only humans, investigators at the Scripps Research Institute used SCID mice to model human viral infection. SCID (severe combined immunodeficiency) mice lack an immune system; therefore, when researchers transplanted human immune system cells into the mice, the cells proliferated and were not rejected. The mice were then exposed to HIV directly isolated from infected patients. The virus was able to infect the human cells within the mice, to replicate, and to reach steady state concentrations of more than 10,000 copies/ml in the blood. When the mice were treated with PRO 140, viral concentrations rapidly decreased more than 20-fold to undetectable levels (<400 copies/ml, the lower limit of detection for the as-say) and remained undetectable for up to nine days. Infected mice given a control antibody maintained uniformly high HIV concentrations.

A single dose of PRO 140 was highly effective in reducing HIV viral loads in these ani-mals,” said Dennis R. Burton, Ph.D., Professor of Immunology at the Scripps Research Institute, La Jolla, CA, and one of the study’s authors. Previously, Dr. Burton had used this mouse model of HIV infection to test other antibodies that effectively blocked HIV in vitro. “Interestingly, we found that PRO 140 was much more effective than other antibodies we’ve tested in this model. These findings highlight the promise of CCR5-targeting therapies in general and PRO 140 in par-ticular,” Burton added.

Progenics has a development and license agreement with Protein Design Labs, Inc. to de-velop a humanized version of PRO 140 that retains the antibody’s antiviral activity but which is less immunogenic and therefore optimized for prolonged use in patients.

Progenics Pharmaceuticals, Inc., Tarrytown, NY, is a biopharmaceutical company fo-cusing on the development and commercialization of products for the treatment and prevention of viral, cancer, and other life-threatening diseases. The Company applies its immunological exper-tise to develop biopharmaceuticals to fight viral diseases, such as human immunodeficiency virus (HIV) infections, and cancers, such as malignant melanoma and prostate cancer. The Company has initiated Phase II clinical trials of its lead HIV product, PRO 542, a viral-entry inhibitor. The Company is developing follow-on product candidates in HIV infection: PRO 367 has completed a Phase I study, PRO 140 is preparing to commence Phase I/II trials, and a lead therapeutic candi-date has been selected from a novel class of anti-HIV compounds known as sulfated CCR5 pep-tides. The Company is also engaged in programs to discover and develop small-molecule HIV therapeutics that target the fusion co-receptors of the virus and other programs focusing on HIV attachment and fusion. The Company is developing cancer immunotherapies based on PSMA (prostate specific membrane antigen) technology. The Company’s most clinically advanced product, GMK, is a cancer vaccine in a pivotal Phase III clinical trial for the treatment of malig-nant melanoma. Progenics is also prepared to commence Phase II trials with a second cancer vaccine, MGV, with broad application to a variety of cancers. The Company is also developing a novel small-molecule antioxidant, dehydroascorbic acid (DHA), to treat stroke and other disorders.

This press release contains forward-looking statements. Any statements contained herein that are not statements of historical fact may be forward-looking statements. When the Company uses the words ‘anticipates,’ ‘plans,’ ‘expects’ and similar expressions they are identifying forward-looking statements. Such forward-looking statements involve risks and uncertainties which may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by for-ward-looking statements. Such factors include, among others, the uncertainties associated with product development, the risk that clinical trials will not commence when or proceed as planned, the risks and un-certainties associated with dependence upon the actions of the Company’s corporate, academic and other collaborators and of government regulatory agencies, the risk that products that appear promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the uncertainty of future profit-ability and other factors set forth more fully in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2000 and other periodic filings with the Securities and Exchange Commission to which investors are referred for further information. In particular, the Company cannot assure you that any of the their programs will result in a commercial product. The Company does not have a policy of up-dating or revising forward-looking statements, and thus it should not be assumed that the Company’s si-lence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.

Das war alles Euer Donkosak-Grischka